ALLOGENE THERAP. DL-,001 Aktie

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?» Mehr auf zacks.com

Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,345 shares of the company’s stock after selling 168,152 shares during the period. Squarepoint Ops LLC’s holdings in Allogene Therapeutics were worth $43,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently bought and sold shares of ALLO. Lynx1 Capital Management LP lifted its position in Allogene Therapeutics by 75.3% during the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock valued at $23,163,000 after acquiring an additional 4,672,349 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $7,345,000. Patient Square Capital LP purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $3,174,000. Gilead Sciences Inc. purchased a new stake in Allogene Therapeutics during the fourth quarter valued at approximately $2,464,000. Finally, Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 30.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after acquiring an additional 831,146 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock. Allogene Therapeutics Trading Up 3.5% NASDAQ ALLO opened at $1.46 on Wednesday. The company has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.74. Allogene Therapeutics, Inc. has a 12-month low of $0.86 and a 12-month high of $3.78. The stock has a market cap of $319.35 million, a P/E ratio of -0.94 and a beta of 0.31. Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). As a group, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year. Insider Buying and Selling In related news, CEO David D. Chang sold 46,668 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 61,757 shares of company stock valued at $115,873 over the last 90 days. Insiders own 13.20% of the company’s stock. Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the stock. Citizens Jmp cut shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 14th. Robert W. Baird decreased their target price on shares of Allogene Therapeutics from $12.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Oppenheimer decreased their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. HC Wainwright decreased their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 19th. Finally, Truist Financial decreased their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44. Get Our Latest Research Report on ALLO Allogene Therapeutics Company Profile (Free Report) Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). See Also Five stocks we like better than Allogene Therapeutics What is a Microcap Stock? Everything You Need to Know AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is Put Option Volume? Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Small Caps With Big Return Potential Government Mandate Sends eVTOL Stocks Flying» Mehr auf defenseworld.net

Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).» Mehr auf zacks.com